Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsNeed more proof that Vivek Ramaswampy is nothing but a snake-oil salesman? Ok...
Must-watch video describing how Vivek is a slimey grifter that would give even Bobby Axlerod the shivers
The drug in question failed FOUR trials
After Vivek bought it for practically nothing, he altered one study, even put his moms name on it, to make it seem like it was successful
After a subsequent study showed that the drug was completely ineffectual, the stock tanked 99% in one day
Link to tweet
And a little more
Why Axovant's $315M IPO bonanza should scare the hell out of you
By John Carroll
Jun 11, 2015 10:41am
https://www.fiercebiotech.com/biotech/why-axovant-s-315m-ipo-bonanza-should-scare-hell-out-of-you
The bare bones of Ramaswamy's new biotech venture, Axovant ($AXON), are much discussed these days. The former hedge fund manager grabbed an abandoned GlaxoSmithKline drug for Alzheimer's for $5 million. He gathered a team together and without recruiting a single patient for a pivotal study of a marginal drug designed to treat symptoms of the disease, just raised $315 million in an upsized IPO that came in at the top of the range and promptly gyrated much higher today as investors bought in.
Axovant, with no track record, no experience and one questionable product, leaped onto the market worth much more than $1 billion.
Given the fact that GlaxoSmithKline had a chance to take a look at this drug in the clinic, and concluded that they couldn't do better than selling it for lunch money, the IPO terms illustrate the kind of overnight riches a select few can find on Wall Street, provided you have the right kind of friends with money.
Axovant, with no track record, no experience and one questionable product, leaped onto the market worth much more than $1 billion.
Given the fact that GlaxoSmithKline had a chance to take a look at this drug in the clinic, and concluded that they couldn't do better than selling it for lunch money, the IPO terms illustrate the kind of overnight riches a select few can find on Wall Street, provided you have the right kind of friends with money.
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
3 replies, 1064 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (10)
ReplyReply to this post
3 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
Need more proof that Vivek Ramaswampy is nothing but a snake-oil salesman? Ok... (Original Post)
Roland99
Aug 2023
OP
InAbLuEsTaTe
(24,122 posts)1. Shocker!! NOT!! Sounds like your typical sleeze-ball Rethuglian!!
😱😱😱😱😱
Zambero
(8,965 posts)2. Grifting, medical fakery, misrepresentation, and bankruptcy are GOP badges of honor
The current GOP frontrunner has repeatedly demonstrated that nobody does snake oil better. Ramaswamy is eager to grab that torch, but, bonafide slime factors notwithstanding, he has a long and steep hill to climb before pulling even with the current champion.
mobeau69
(11,156 posts)3. Nope. I figured that out some time ago.